This extraordinary psychedelic precision functional mapping dataset is now fully/freely available to all! All the info to access & use it in a newly published Nature Scientific Data Resource: rdcu.be/epxe7 Thanks to the incredible team who created it - Subha S, Rick

An overview describes anhedonia’s significance as both a symptom and diagnostic marker, prevalence, and pathophysiological underpinnings. bit.ly/4ipvTNP

Hard to believe it’s been 5 years since we lost Todd Mainprize. An incredible surgeon, teacher, father, husband and friend. Miss our coffees between cases, his sage (and always true) advice, and bottomless well of generosity, of time and knowledge. Always remembered, Sunnybrook Health Sciences Centre

Efficacy and safety of low-versus high-dose-LSD-assisted therapy in patients with major depression: A randomized trial. cell.com/med/fulltext/S…

Comparing Antidepressant Effects of Psilocybin-Assisted Psychotherapy in Individuals That Were Unmedicated at Initial Screening Versus Individuals Discontinuing Medications for Study Participation journals.sagepub.com/doi/10.1177/07…

We have a new Faculty position available in our Dept. Please share and repost. jobs.utoronto.ca/job/Toronto-As…

Viewpoint explores potential justifications underlying the U.S. FDA rejection of methylenedioxymethamphetamine (MDMA) as a treatment for posttraumatic stress disorder. ja.ma/4kMvZ46

Exploring everything from the impact of mitochondrial DNA variants on the risk for schizophrenia to mystical experiences as a predictor of the outcomes of psilocybin-assisted psychotherapy, our #DPRD2025 breakout oral presentations are underway!

UHN and CAMH are bridging the gap between physical and mental health care. The partnership marks a transformation in integrated care in Canada – and the world. Learn more in Toronto Star op-ed by UHN and CAMH CEOs Dr. Kevin Smith and Sarah Downey. READ: thestar.com/opinion/contri…

“Approval rates significantly declined from 2022 to 2024 [...] In 2022, 74 of the 90 (82%) requests were approved, followed by 123 out of 165 (74.5%) in 2023 and 107 out of 181 (59.1%) in 2024, even though the number of overall requests remained stable.” nature.com/articles/s4422…

Great news and yet another significant step forward for psychedelic medicine! Today, atai Life Sciences and Beckley Psytech announced (very!) positive topline results from the long-awaited Phase 2b trial of a single dose of BPL‑003 (5-MeO-DMT) in 193 patients living with

Esketamine nasal spray as a monotherapy improved depressive symptoms in treatment-resistant depression (TRD) compared to placebo. ja.ma/3ZYkZIv

Single-dose (10 mg) psilocybin reduces symptoms in adults with OCD: A pharmacological challenge study: sciencedirect.com/science/articl…

Systematic review and meta-analysis: Stopping antidepressants leads to slight symptom increases compared to placebo, but these symptoms are not clinically significant and do not include mood changes. ja.ma/4lNdBIu

Esketamine and ketamine associate with lower reporting most aspects of suicidality to the WHO Pharmacovigilance database Thanks to Angela Kwan from my research team in leading this report pubmed.ncbi.nlm.nih.gov/40637548/

1/ Just out in Nature Medicine : we show the opioid system modulates ketamine’s effects in major depressive disorder, with naltrexone pre‑treatment reducing acute glutamatergic activity and acute antidepressant effects. nature.com/articles/s4159…

🎉 Congratulations to Newton Cho, the 2025 winner of the Science & PINS Prize for Neuromodulation for his work identifying a novel therapeutic target to improve walking after spinal cord injury. Learn more: scim.ag/3U8Vxwt

Viewpoint: Ketamine's antidepressant potential is hindered by commercial barriers, highlighting the need for a federal program to prioritize drug repurposing based on patient needs. ja.ma/4eweJ0B

Excellent write-up on some of our recent findings. BBRFoundation Researchers Trace How Ketamine Acts on Specific Brain Circuits and Synapses to Relieve Anhedonia | Brain & Behavior Research Foundation bbrfoundation.org/content/resear…

This survey reports that 85% of academics studying psychedelics report their own personal experience with psychedelics It will be important to have independent third-party raters evaluate outcomes in psychedelic studies to manage expectancy biases pubmed.ncbi.nlm.nih.gov/40788485/